Does the world's bestselling asthma drug sometimes kill the patients it is supposed to help? Frank A. Dittig was recovering from a nasty bout of pneumonia in the spring of 2004 when he developed a ...
Millions of Americans rely on asthma medications to manage a potentially life-threatening condition, but affordability ...
GlaxoSmithKline plc (GSK) today announced results from the 'LABA' (long acting beta 2-agonist) safety study, AUSTRI(SAS115359). The study compared Advair ® Diskus ®, a combination of the LABA, ...
Lannett has submitted an ANDA to the Food and Drug Administration for its strategic partner, Respirant's fluticasone propionate and salmeterol inhalation powder (100/50 mcg, 250/50 mcg and 500/50 mcg) ...
Lannett has entered into an exclusive U.S. distribution agreement for Respirent’s generic Advair Diskus (fluticasone propionate – salmeterol xinafoate powder inhaler), which is still pending approval ...
GlaxoSmithKline has confirmed it will face a challenging 2019 as generics of its big-selling Advair drug finally reach the US, as it continues the transformation of its business. The FDA approved the ...
LONDON (Reuters) - GlaxoSmithKline (GSK.L) received a boost on Monday from a decision by Express Scripts (ESRX.O), the largest U.S. pharmacy benefit manager, to reinstate its top-selling lung drug ...
GSK can breathe easy as new CEO Emma Walmsley takes over, following the FDA rejection of Mylan’s generic version of big-selling respiratory drug Advair. The US patent on Advair (fluticasone+salmeterol ...
LONDON (Reuters) - GlaxoSmithKline (GSK.L) is putting more marketing muscle behind its new lung drugs and is looking for a sales boost as top respiratory experts gather to analyse clinical trials data ...
GlaxoSmithKline is shifting its sales strategy for therapy Advair to stress increasing a treatment for chronic obstructive pulmonary disease (COPD), a new report states.Advair, a long-acting beta2 ...
April 20 (Reuters) - Teva Pharmaceutical Industries Ltd on Thursday launched an asthma inhaler that will be the first direct competition to GlaxoSmithKline's best-selling Advair. Teva, which won U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results